<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • <z:chebi fb="0" ids="6801">Metformin</z:chebi>, a <z:chebi fb="0" ids="3095">biguanide</z:chebi> <z:chebi fb="105" ids="17234">glucose</z:chebi> lowering agent, is commonly used to manage type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>. • The molecular mechanisms of <z:chebi fb="0" ids="6801">metformin</z:chebi> have not been fully identified, but turnover of biomarkers such as <z:chebi fb="105" ids="17234">glucose</z:chebi> and signalling pathways or translocation of <z:chebi fb="105" ids="17234">glucose</z:chebi> transporters are closely related to the <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effects of <z:chebi fb="0" ids="6801">metformin</z:chebi>. • The PK/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> of <z:chebi fb="0" ids="6801">metformin</z:chebi> have been investigated in healthy humans and patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and modelling has been performed using an indirect response model </plain></SENT>
<SENT sid="1" pm="."><plain>WHAT THIS STUDY ADDS • The purpose of this investigation was to develop a population PK/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> model for <z:chebi fb="0" ids="6801">metformin</z:chebi> using a signal transduction model in healthy humans and predict the PK/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> profile in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>. • The aim was to compare a previous model (a biophase model) with the signal transduction model, and use a more appropriate model to follow the actions of <z:chebi fb="0" ids="6801">metformin</z:chebi>. • Additionally, our developed model was appropriate to predict the time course of plasma <z:chebi fb="0" ids="6801">metformin</z:chebi> and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) concentrations in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>. • To our knowledge, this is the first published population PK/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> analysis using the signal transduction model for <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS To develop a population pharmacokinetic (PK) and pharmacodynamic (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>) model for <z:chebi fb="0" ids="6801">metformin</z:chebi> (500 mg) using the signal transduction model in healthy humans and to predict the PK/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e> profile in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS Following the oral administration of 500 mg <z:chebi fb="0" ids="6801">metformin</z:chebi> to healthy humans, plasma concentrations of <z:chebi fb="0" ids="6801">metformin</z:chebi> were measured using LC-MS/MS </plain></SENT>
<SENT sid="4" pm="."><plain>A sequential modelling approach using NONMEM VI was used to facilitate data analysis </plain></SENT>
<SENT sid="5" pm="."><plain>Monte Carlo simulation was performed to predict the antihyperglycaemic effect in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS Forty-two healthy humans were included in the study </plain></SENT>
<SENT sid="7" pm="."><plain>Population mean estimates (relative standard error, RSE) of apparent clearance, apparent volume of distribution and the absorption rate constant were 52.6 l h(-1) (4.18%), 113 l (56.6%) and 0.41 h(-1) , respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Covariate analyses revealed that <z:chebi fb="0" ids="16737">creatinine</z:chebi> clearance (CL(CR) ) significantly influenced <z:chebi fb="0" ids="6801">metformin</z:chebi>: CL/F= 52.6 × (CL(cr) /106.5)(0.782)  </plain></SENT>
<SENT sid="9" pm="."><plain>The signal transduction model was applied to describe the antihyperglycaemic effect of <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The population means for efficacy, potency, transit time and the Hill coefficient were estimated to be 19.8 (3.17%), 3.68 µg ml(-1) (3.89%), 0.5 h (2.89%) and 0.547 (9.05%), respectively </plain></SENT>
<SENT sid="11" pm="."><plain>The developed model was used to predict the antihyperglycaemic effect in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="12" pm="."><plain>The predicted plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration value was similar to previous values </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS The population signal transduction model was developed and evaluated for <z:chebi fb="0" ids="6801">metformin</z:chebi> use in healthy volunteers </plain></SENT>
<SENT sid="14" pm="."><plain>Model evaluation by non-parametric bootstrap analysis suggested that the proposed model was robust and parameter values were estimated with good precision </plain></SENT>
</text></document>